glp-1 and kidney function receptor agonists next-generation metabolic hormone therapies in chronic disease Glucagon-like Peptide-1 Receptor Agonists and

It is a microbiome-based approach to supporting one of the body most studied metabolic hormones

Using the 2 CT method [ relative expression (fold change) of forkhead box O1 (FoxO1) (5-AGCTCAAACGCTAGCACCAT-3 and 5-GGTGGATACACCAGGGAATG-3), glucagon (5-GCCGAGCAAGGCGAGACT-3and 5-CATGTCTGCGCCCAAGTTC-3), insulin (5-CCTGCCCAGGCTTTTGTCA-3 and 5-GGTGCAGCACTGATCCACAATG-3), X-box binding protein 1 (XBP1) (5-GGTCTCAGAGGCAGAGTCCAAG-3 and 5-AGAGGCAACAGCGTCAGAATCC-3), Hspa5(BIP) (5-GAGGACAAGAAGGAGGATG-3 and 5-TTGGACGTGAGTTGGTTC-3), IL6 (5-GTCAACTCCATCTGCCCTTC-3 and 5-TGTGGGTGGTATCCTCTGTG-3), IL1 (5-GCCAACAAGTGGTATTCTCCA-3 and 5-TGCCGTCTTTCATCACACAG-3), HIF (5-TGGATGGCTTTGTTATGGTG-3 and 5-TGGTCACATGGATGGGTAAA-3), and GAPDH (5-TTAAGGGCATCCTGGGCTACACT-3 and 5-TTACTCCTTGGAGGCCATGTAGG-3) was normalized to -actin (5-GTCGTACCACTGGCATTGTG-3 and 5-CTCTCAGCTGTGGTGGTGAA-3) as the most suitable reference gene (expression level unaffected by the experimental treatment) and relative to the sham group as the calibrator

The impact of microbial metabolites on vascular function and its potential of targeting gut microbiota to modulate redox balance and BP is a promissory gate to bettering HTN syndrome (Li et al., 2021)

even though social media is not necessarily representative, a large collection of posts may reflect additional concerns. The researchers caution that their findings are not causal

A nephrologist perspective on obesity: from kidney injury to clinical management